Join CEO Josh Bartch at the Sequire Cannabis & Psychedelic Conference on April 20th at 11 am ET to learn more about Mydecine and what's in store for 2022! Register or learn more here: cannabis-conference22.mysequire.com SRAX

In the 1st year of the COVID-19 pandemic, the prevalence of anxiety and depression worldwide increased by 25%, according to a WHO brief released earlier this month (bit.ly/378Lwu8). Learn how we're developing innovative treatments to address this by visiting our website.

This week in the blog, Dr. Rakesh Jetly, Chief Medical Officer at Mydecine Innovations, Inc. (Mydecine Innovations Group), shares his thoughts on Health Canada’s recent SAP revision to include psychedelics in its Special Access Program. Check out the article here: psychedelicstoday.com/2022/04/01/can…

Today we celebrate #WorldHealthDay & reiterate our commitment to promoting health & well-being by creating new therapies for patients. Let’s keep pushing forward to remove stigmas around #mentalhealth & create safe, evidence-based medicines for a #HealthierTomorrow!

My new story looks at the ways donors influence psychedelic science. Excited to be contribute for the first time to Lucid News. #psychedelics #philanthropy Tim Ferriss Heffter Research Mydecine Innovations Group lucid.news/funders-at-joh…

Great read by MarcGunther touching on the behind-the-scenes aspects of funding psychedelic research and Matthew W. Johnson's groundbreaking work in this field! Lucid News $MYCO.NE $MYCOF #MedicineEvolved #psychedelicscience Full Story: bit.ly/3LY7FtU

Psilocybin has the ability to increase neuroplasticity, the brain's ability to change through growth & reorganization of its neural networks, giving patients an opportunity to treat their raw addiction rather than just treating their symptoms. bit.ly/3uXoeAR TIME

The first Earth Day took place on April 22, 1970. Today we celebrate 52 years of #EarthDay! Learn more: epa.gov/earthday

.If you missed CEO Josh Bartch's presentation at the Sequire Cannabis and Psychedelics Conference, you can click the link below to catch the replay!

We are proud to be a sponsor of this study at Macquarie University, led by Mydecine Advisory Board member Dr. Vince Polito, assessing psilocybin as an antidepressant. According to World Health Organization (WHO), roughly 280 million people globally suffer from depression. Learn more: bit.ly/3vkd9cZ

Would really appreciate it if you could consider donating to this cause: gofund.me/bd099d2e

MYCO-004 is a short-acting, skin-permeable, patch-delivered #tryptamine compound that has a faster onset time with reduced side effects compared to classic #psilocybin. These features enable better integration into our existing #healthcare infrastructure. bit.ly/3hGBDWy

.It's been over 70 years since the first observations of PTSD were recorded, and yet there still aren't many great treatment options widely available. The time for new treatments is now!

Europe’s 1st commercial facility for psychedelic drug trials is to open in London! We've started working with Clerkenwell Health to lay the groundwork for future clinical trials in the UK. Full article: bit.ly/3yoGipv

At Mydecine, we have a global team with 100s of years of experience in medicinal chemistry & pharmaceutical drug development, an end-to-end drug development infrastructure under one roof, and a growing library of novel #psychedelic molecules. Learn more: bit.ly/39P7fsm

Created by World Health Organization (WHO) in 1987, #worldnotobaccoday aims to draw attention to the tobacco epidemic. Tobacco growing, manufacturing & use poison our water, soil, beaches & city streets with chemicals, toxic waste, and cigarette butts. Learn how to make a difference:bit.ly/3alUhlW

Today we released an update on our clinical trial and drug development initiatives and welcomed a new member to our board of directors! Full release here:bit.ly/3H7LPmC $MYCO.NE $MYCOF

We're excited to share that the FDA has cleared MYCO-001 in a recent IND application, marking the first clearance of our drug product! Get the full scoop: bit.ly/3mUo1cH ​​$MYCO.NE $MYCOF

#FDA Clears Mydecine Innovations Group's MYCO-001 for Multi-Site Trial in #Smoking Cessation Funded by a $4 million grant from the #NIH, this is the 1st time in 50 years #USA #government has funded a #study evaluating a #psychedelic compound for therapeutic use $MYCOF bakersfield.com/ap/news/u-s-fd…

We've filed our full patent application covering our MYCO-006 family of novel short-acting MDMA analogs! Full story here: bit.ly/3RIIX4B ​​$MYCO.NE $MYCOF #Psychedelics